Im wondering if anyone can point me to any literature discussing the benefits of the AAV2 ITR in manufacturing, therapeutic efficacy, clearance, toxicity, etc.
Not sure why everyone has chosen to opt for crosspackaging over using wildtype helper systems for different serotypes, but the reason must be pretty good for everyone to do it...
I found this paper from 2001 which may help explain things I suppose?
Article Cross-Packaging of a Single Adeno-Associated Virus (AAV) Typ...
Dear Nikhil Goel
this is an interesting question. I have also wondered about it.
I would presume that since AAV2 is the best characterized and rep2 works well with all the available ITRs researchers tend to use it more often. I would be happy if someone can direct me to a more specific reason for the high prevalence of rep2.
However, there have been efforts to use different reps and ITRs as well. You can get more details here-
https://www.cell.com/molecular-therapy-family/methods/pdf/S2329-0501(16)30171-1.pdf
Article Reducing the Risk of Adeno-Associated Virus (AAV) Vector Mob...
You might find this preprint also very relevant- Preprint Improved Genome Packaging Efficiency of AAV Vectors Using Rep Hybrids
best wishes
- Badges
- Science topic
- Similar topics
- Biological Science
- Biochemistry
- Enzymology
- Enzymes